Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Image File
Original HTML

SOUTH SAN FRANCISCO, Calif., Oct. 2, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 35,275 restricted stock units to 18 non-executive employees vesting over four years with 25% of the grant vesting each year.

About Rigel

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, its marketed products and pipeline of potential products, please visit www.rigel.com.

Contact for Investors & Media

Rigel Pharmaceuticals, Inc. 

650.624.1232

ir@rigel.com

SOURCE Rigel Pharmaceuticals, Inc.

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Rewritten
Dedupe hash
prn_302896740
Press Eligible
Yes
Press Eligible Reason
Corporate announcement of employee inducement stock grants by a biotechnology company.
Source Name
Unknown Company
Original Summary

<p>SOUTH SAN FRANCISCO, Calif., Oct. 2, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and...</p>

Original Link
Original Source
Image URL
https://mmx.prnewswire.com/media/MS473286/Rigel-R-Logo.jpg?id=OA2984019&p=facebook
Content Hash (SHA-256, erste 32 hex)
672de9880d9bdf50687181617a400d02